Boston Therapeutics has a new tablet PAZ320 designed to reduce a person’s sugar intake by 40%. CEO Dr. David Platt believes the tablet will eventually be approved for non-diabetic patients looking to cut back on the copious amounts of sugar prevalent in many processed foods. The company also makes an intravenous drug that will help diabetic foot ulcers heal more quickly.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
